Replies to post #347040 on NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

Mesenchymal shift? This is contrary I thought to immunotherapy metrics that actually show "More" mutations are better which presumably allow the immune system to identify enemy cells over good cells from their genetic mutations.

[flipper44]

It’s an incomplete article. The immunotherapeutics they are talking about are CI and poliovirus strategies. Those are generalist therapies, and as monotherapies, have not proven they can fight GBM.

DCVax-l is also an immunotherapeutic, but a different kind, and it works best against tumors with high mutation, because it targets the tumor’s antigen mutations, and it’s phase iii trial against a cross section of all four types of GBM will be looked at.

Of course, the article is just dumb, in that it doesn’t report that low mutational tumors, like proneural, have, on average, longer survival than high mutation tumors anyway. Ugh. (Duke flailing)